Rani therapeutics is developing a novel approach for the oral delivery of large drug molecules including peptides, proteins and antibodies.
Rani Therapeutics announced that it has closed its latest round of funding, bringing the company’s total investment to more than $70 million (Feb 2016). New investors include AstraZeneca, Virtus Inspire Ventures, and Ping An Ventures. Existing investors in Rani Therapeutics include Novartis, Google Ventures, Buttonwood, GF Ventures, KPC Pharmaceuticals, InCube Ventures and VentureHealth, among others. The funding will support expansion of the team, new facilities and manufacturing scale up
